drugset
drugset / Trial / NCT04975204

A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors

NCT04975204 ↗

Phase 1 Unknown 126 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein. By binding to BCL-2 protein, TQB3909 releases Pro apoptotic proteins such as BCL-2-Anatagonist/Killer 1(BAK), BCL-2 associated X (BAX) protein and BCL-2 associated death (BAD) protein, promotes the release of cytochrome c from mitochondria, phosphatidylserine eversion, stimulates caspase 3 / 7 activity and caspase 3 / 9 cleavage, and induces apoptosis.

Timeline

Start
2022-02-18
Primary completion
2022-12
Completion
2024-08

Drugs

EvaluationDrugModalityDoseRoute
Subject TQB3909 Unknown 100 mg Oral
Subject TQB3909 Unknown 1200 mg Oral

Indications

cancer